Aripiprazole (ARIPIPRAZOLE ORAL)
Aripiprazole (ARIPIPRAZOLE ORAL) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Aripiprazole; Generic name: ARIPIPRAZOLE ORAL; Drug class: Atypical Antipsychotic [EPC].
| Brand name | Aripiprazole |
|---|---|
| Generic name | ARIPIPRAZOLE ORAL |
| Drug class | Atypical Antipsychotic [EPC] |
| Manufacturer | ATLANTIC BIOLOGICALS CORP. |
| Used for | 1 INDICATIONS AND USAGE Aripiprazole oral solution is indicated for the treatment of: • Schizophrenia [see Clinical Studies (14.1) ] • Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder [see Clinical Studies (14.2) ] • Irritability Associated with Autistic Disorder [see Clinical Studies (14.4) ] • Treatment of Tourette’s Disorder [see Clinical Studies (14.5) ] Aripiprazole oral solution is an atypical antipsychotic. The oral formulations are indicated for: • Schizophrenia (14.1) • Acute Treatment of Manic and Mixed Episodes associated with Bipolar I (14.2) • Irritability Associated with Autistic Disorder (14.4) • Treatment of Tourette’s disorder (14.5) |
| Dosage | 2 DOSAGE AND ADMINISTRATION Initial Dose Recommended Dose Maximum Dose Schizophrenia – adults (2.1) 10 to 15 mg/day 10 to 15 mg/day 30 mg/day Schizophrenia – adolescents (2.1) 2 mg/day 10 mg/day 30 mg/day Bipolar mania – adults: monotherapy (2.2) 15 mg/day 15 mg/day 30 mg/day Bipolar mania – adults: adjunct to lithium or valproate (2.2) 10 to 15 mg/day 15 mg/day 30 mg/day Bipolar mania – pediatric patients: monotherapy or as an adjunct to lithium or valproate (2.2) 2 mg/day 10 mg/day 30 mg/day I |
| Warnings | WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; AND SUICIDAL THOUGHTS AND BEHAVIORS WITH ANTIDEPRESSANT DRUGS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Aripiprazole oral solution is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1) ]. Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, |
| Active ingredient(s) | ARIPIPRAZOLE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=042b725c-1c17-4cfb-80b2-c841226d795e |